Our findings that decreasing endolysosomal cholesterol with PRX suppressed inflammatory activation of macrophages and atherogenesis and that the cholesterol level in circulating monocytes was associated with the severity of atherosclerosis in humans strongly suggest that macrophage cellular cholesterol metabolism is an attractive diagnostic and therapeutic target for the treatment of inflammatory diseases, including atherosclerosis. This evidence concerns the gene PRX and atherosclerosis.